미국의 STI 및 질염 PCR 검사 시장 : 규모, 점유율, 동향 분석, 병태별, 검사 유형별, 최종 용도별, 부문 예측(2025-2030년)

U.S. STI & Vaginitis PCR Testing Market Trends:

The U.S. STI & vaginitis PCR testing market size was estimated at USD 240.72 million in 2024 and is projected to grow at a CAGR of 8.2% from 2025 to 2030. The increasing prevalence of sexually transmitted infections and growing patient awareness are driving demand for advanced diagnostic tools. The Centers for Disease Control and Prevention (CDC) continues to report millions of new STI cases each year, with chlamydia, gonorrhea, and trichomoniasis among the most reported. This rise in infections has created a pressing need for early and accurate detection methods. Polymerase chain reaction (PCR) tests provide high sensitivity and specificity, offering a reliable alternative to traditional diagnostics. As patients and clinicians prioritize quick and accurate results, PCR testing is gaining widespread preference in urban populations, with better access to healthcare facilities and higher testing frequencies, further supporting market expansion. The gradual decline in stigma related to STI screening also plays a vital role in encouraging timely diagnosis.

The integration of PCR testing into routine gynecological and sexual health evaluations in clinics and hospitals is another key driver. Many healthcare providers now recommend regular testing for at-risk populations, enhancing demand for PCR-based solutions. The growing trend of point-of-care testing and at-home sample collection kits has made STI and vaginitis testing more convenient. These innovations support early detection and reduce barriers associated with clinic-based testing. As a result, diagnostic labs and biotech firms are investing in developing user-friendly, rapid PCR kits tailored for the U.S. market. Rising partnerships between diagnostic companies and telehealth platforms expand access to PCR testing services. Increased healthcare spending by private insurers and employers also supports wider adoption of advanced diagnostic technologies.

Technological advancements in multiplex PCR platforms are improving the efficiency of STI and vaginitis testing. These innovations allow the simultaneous detection of multiple pathogens from a single sample, reducing costs and turnaround time. Such developments are particularly valuable for managing co-infections, which are common among patients with STIs. Furthermore, ongoing research into microfluidic PCR devices and automated sample preparation enhances laboratory throughput. This progress benefits large diagnostic networks and independent U.S. labs facing rising testing volumes. The competitive landscape is also evolving, with leading players launching novel PCR assays targeting hard-to-detect organisms. As these advanced diagnostics become more accessible, the overall market will witness consistent revenue growth through 2030.

Trichomoniasis remains a significant concern, especially in women, with recent studies emphasizing its link to adverse pregnancy outcomes, prompting wider use of molecular testing. Herpes Simplex Virus (HSV-1 & HSV-2) continues to see widespread testing due to its recurrent nature and asymptomatic shedding, with new rapid PCR assays gaining FDA approval for quicker diagnosis. Human Papillomavirus (HPV) testing is essential for identifying high-risk strains linked to cervical and other cancers, as seen in the adoption of the latest FDA-approved HPV assays like Roche's Cobas HPV test for early cancer screening. Syphilis and other STIs, though less common, are included in multiplex panels to ensure comprehensive detection and early intervention, with multiplex PCR panels recently validated in clinical studies for improved sensitivity.

U.S. STI & Vaginitis PCR Testing Market Report Segmentation

This report forecasts country revenue growth and analyzes the latest industry trends in each sub-segment from 2018 to 2030. For this study, Grand View Research has segmented the U.S. STI & vaginitis PCR testing market report based on condition, test type, and end use.

• Condition Outlook (Revenue, USD Million, 2018 - 2030)
• Sexually Transmitted Infections (STIs)
  • Chlamydia
  • Gonorrhea
  • Trichomoniasis
  • Herpes Simplex Virus (HSV-1 & HSV-2)
  • Human Papillomavirus (HPV)
  • Syphilis
  • Other
• Vaginal Infections
  • Bacterial Vaginosis
  • Vulvovaginal Candidiasis
  • Others
• Test Type Outlook (Revenue, USD Million, 2018 - 2030)
• STI PCR Panels
• Vaginitis PCR Panels
• End Use Outlook (Revenue, USD Million, 2018 - 2030)
• Hospitals and Clinics
• Diagnostic Laboratories
• Homecare/At-home Testing
• Others

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Condition
  • 1.2.2. Test Type
  • 1.2.3. End Use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. STI & Vaginitis PCR Testing Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. U.S. STI & Vaginitis PCR Testing Market: Condition Business Analysis

• 4.1. Condition Market Share, 2024 & 2030
• 4.2. Condition Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Condition, 2018 to 2030 (USD Million)
• 4.4. Sexually Transmitted Infections (STIs)
  • 4.4.1. Sexually Transmitted Infections (STIs) Market, 2018 - 2030 (USD Million)
  • 4.4.2. Chlamydia
    • 4.4.2.1. Chlamydia Market, 2018 - 2030 (USD Million)
  • 4.4.3. Gonorrhea
    • 4.4.3.1. Gonorrhea Market, 2018 - 2030 (USD Million)
  • 4.4.4. Trichomoniasis
    • 4.4.4.1. Trichomoniasis Market, 2018 - 2030 (USD Million)
  • 4.4.5. Herpes Simplex Virus (HSV-1 & HSV-2
    • 4.4.5.1. Herpes Simplex Virus (HSV-1 & HSV-2) Market, 2018 - 2030 (USD Million)
  • 4.4.6. Human Papillomavirus (HPV)
    • 4.4.6.1. Human Papillomavirus (HPV) Market, 2018 - 2030 (USD Million)
  • 4.4.7. Syphilis
    • 4.4.7.1. Syphilis Market, 2018 - 2030 (USD Million)
  • 4.4.8. Other
    • 4.4.8.1. Other Market, 2018 - 2030 (USD Million)
• 4.5. Vaginal Infections
  • 4.5.1. Vaginal Infections Market, 2018 - 2030 (USD Million)
  • 4.5.2. Bacterial Vaginosis
    • 4.5.2.1. Bacterial Vaginosis Market, 2018 - 2030 (USD Million)
  • 4.5.3. Vulvovaginal Candidiasis
    • 4.5.3.1. Vulvovaginal Candidiasis Market, 2018 - 2030 (USD Million)
  • 4.5.4. Others
    • 4.5.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. U.S. STI & Vaginitis PCR Testing Market: Test Type Business Analysis

• 5.1. Test Type Market Share, 2024 & 2030
• 5.2. Test Type Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Test Type, 2018 to 2030 (USD Million)
• 5.4. STI PCR Panels
  • 5.4.1. STI PCR Panels Market, 2018 - 2030 (USD Million)
• 5.5. Vaginitis PCR Panels
  • 5.5.1. Vaginitis PCR Panels Market, 2018 - 2030 (USD Million)

Chapter 6. U.S. STI & Vaginitis PCR Testing Market: End Use Business Analysis

• 6.1. End Use Market Share, 2024 & 2030
• 6.2. End Use Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 6.4. Hospitals and Clinics
  • 6.4.1. Hospitals and Clinics, 2018 - 2030 (USD Million)
• 6.5. Diagnostic Laboratories
  • 6.5.1. Diagnostic Laboratories Market, 2018 - 2030 (USD Million)
• 6.6. Homecare/At-home Testing
  • 6.6.1. Homecare/At-home Testing Market, 2018 - 2030 (USD Million)
• 6.7. Others
  • 6.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. Becton, Dickinson and Company (BD)
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Type Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. F. Hoffmann-La Roche Ltd.
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Type Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. Hologic, Inc.
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Type Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. Abbott
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Type Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. Danaher Corporation (Cepheid)
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Type Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. Seegene Inc.
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Type Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. bioMerieux (BioFire Diagnostics)
    • 7.5.7.1. Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Type Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. QIAGEN
    • 7.5.8.1. Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Type Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. Thermo Fisher Scientific, Inc.
    • 7.5.9.1. Overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Type Benchmarking
    • 7.5.9.4. Strategic Initiatives
  • 7.5.10. DiaSorin S.p.A (Luminex)
    • 7.5.10.1. Overview
    • 7.5.10.2. Financial Performance
    • 7.5.10.3. Type Benchmarking
    • 7.5.10.4. Strategic Initiatives
  • 7.5.11. Sansure Biotech Inc
    • 7.5.11.1. Overview
    • 7.5.11.2. Financial Performance
    • 7.5.11.3. Type Benchmarking
    • 7.5.11.4. Strategic Initiatives
  • 7.5.12. R-Biopharm AG
    • 7.5.12.1. Overview
    • 7.5.12.2. Financial Performance
    • 7.5.12.3. Type Benchmarking
    • 7.5.12.4. Strategic Initiatives
  • 7.5.13. altona Diagnostics GmbH
    • 7.5.13.1. Overview
    • 7.5.13.2. Financial Performance
    • 7.5.13.3. Type Benchmarking
    • 7.5.13.4. Strategic Initiatives
  • 7.5.14. CERTEST BIOTEC.
    • 7.5.14.1. Overview
    • 7.5.14.2. Financial Performance
    • 7.5.14.3. Type Benchmarking
    • 7.5.14.4. Strategic Initiatives